Annick de Vries

3.1k citations

90 papers · 1.9k indexed · h-index 25

Immunology top 5%
Genetics top 5%
Physiology top 10%
Cellular and Molecular Neuroscience top 5%
Epidemiology top 10%

Co-authors: Theo Rispens Ferdi Engels Paul A. J. Henricks Jonathan R. Seckl Mark C. Dessing Frans P. Nijkamp FRANS P. NIJKAMP Geert D’Haens
Topics: Inflammatory Bowel Disease (17 papers)Biosimilars and Bioanalytical Methods (17 papers)Microscopic Colitis (15 papers)
Cited by: Developmental Neuroscience Behavioral Neuroscience Biological Psychiatry
Journals: Journal of Clinical Investigation Gastroenterology PLoS ONE
Partner nations: Netherlands Belgium United Kingdom

In The Last Decade

Annick de Vries

86 papers receiving 1.9k citations

Peers

Countries citing papers authored by Annick de Vries

Since Specialization

Citations

This map shows the geographic impact of Annick de Vries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annick de Vries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annick de Vries more than expected).

Fields of papers citing papers by Annick de Vries

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annick de Vries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annick de Vries. The network helps show where Annick de Vries may publish in the future.

Co-authorship network of co-authors of Annick de Vries

This figure shows the co-authorship network connecting the top 25 collaborators of Annick de Vries. A scholar is included among the top collaborators of Annick de Vries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annick de Vries. Annick de Vries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial 2025 ·Annals of the Rheumatic Diseases ·(unknown),(unknown),Gertjan Wolbink,Michael T. Nurmohamed,Maarten Boers,Femke Hooijberg,Theo Rispens,Annick de Vries,Ronald van Vollenhoven,Sofía Ramiro,Noortje van Herwaarden,Bart J. F. van den Bemt,Alfons A den Broeder	0
2	To Convert or Not to Convert? Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Considerations and Recommendations for Converting Capillary Blood Microsampling Concentrations to Plasma Concentrations 2025 ·Therapeutic Drug Monitoring ·(unknown),(unknown),(unknown),Theo Rispens,Anders Åsberg,Maria Shipkova,Brenda C. M. de Winter,Dirk Jan A. R. Moes,Annick de Vries,Jan‐Willem C. Alffenaar,Christophe P. Stove	2
3	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology 2024 ·Therapeutic Drug Monitoring ·Dahham Alsoud,Dirk Jan A. R. Moes,Zhigang Wang,(unknown),(unknown),Murray L. Barclay,Tomoyuki Mizuno,Iris K. Minichmayr,Ron J. Keizer,Sebastian G. Wicha,Gertjan Wolbink,Jo Lambert,Séverine Vermeire,Annick de Vries,Konstantinos Papamichael,Núria Padullés Zamora,Erwin Dreesen	8
4	Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial 2023 ·Journal of the European Academy of Dermatology and Venereology ·(unknown),G. E. van der Kraaij,(unknown),Wouter Ouwerkerk,J. M. P. A. van den Reek,S.P. Menting,Errol P. Prens,Theo Rispens,Annick de Vries,E.M.G.J. de Jong,Jo Lambert,Martijn B. A. van Doorn,Phyllis I. Spuls	5
5	Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling 2023 ·Journal of Investigative Dermatology ·(unknown),(unknown),G. E. van der Kraaij,Annelie H. Musters,(unknown),S.P. Menting,Theo Rispens,Annick de Vries,Martijn B. A. van Doorn,Errol P. Prens,Jo Lambert,J. M. P. A. van den Reek,E.M.G.J. de Jong,Ron A. A. Mathôt,Phyllis I. Spuls	3
6	Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more 2023 ·British Journal of Clinical Pharmacology ·(unknown),Dirk Jan A. R. Moes,Sofía Ramiro,Rémy L.M. Mostard,César Magro‐Checa,(unknown),Michiel H. M. Gronenschild,(unknown),Jacqueline Buijs,Annick de Vries,Ralph Peeters,Robert Landewé,Dennis R. Wong	0
7	Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial 2022 ·Journal of Investigative Dermatology ·G. E. van der Kraaij,(unknown),J. M. P. A. van den Reek,S.P. Menting,Annelie H. Musters,Barbara A. Hutten,Menno A. de Rie,Wouter Ouwerkerk,(unknown),Errol P. Prens,Theo Rispens,Annick de Vries,E.M.G.J. de Jong,(unknown),Jo Lambert,Martijn B. A. van Doorn,Phyllis I. Spuls	15
8	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial 2022 ·Journal of Dermatological Treatment ·(unknown),Sophie E. Berends,Hans Groenewoud,Ron A. A. Mathôt,(unknown),J.M. Mommers,Paul M. Ossenkoppele,M.I.A. Koetsier,M.A.M. Berends,Annick de Vries,P.C.M. van de Kerkhof,Alfons A den Broeder,E.M.G.J. de Jong,J. M. P. A. van den Reek	8
9	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study 2021 ·Clinical Pharmacokinetics ·Dirk Jan A. R. Moes,David J. van Westerloo,Sandra M. Arend,Jesse J. Swen,Annick de Vries,Henk‐Jan Guchelaar,Simone A. Joosten,Mark de Boer,Teun van Gelder,Judith van Paassen	10
10	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease 2019 ·Gastroenterology ·Mark Löwenberg,Séverine Vermeire,Nahid Mostafavi,Frank Hoentjen,Denis Franchimont,Peter Bossuyt,Pieter Hindryckx,Theo Rispens,Annick de Vries,C. Janneke van der Woude,Sophie E. Berends,Carmen A. Ambarus,Ron A. A. Mathôt,(unknown),Filip Baert,Geert D’Haens	87
11	Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome 2018 ·Clinical Therapeutics ·Ingrid G. Rekeland,Øystein Fluge,Kine Alme,Kristin Risa,Kari Sørland,Olav Mella,Annick de Vries,Jan Schjøtt	3
12	Role of properdin in complement-mediated kidney diseases 2018 ·Nephrology Dialysis Transplantation ·Mieke F. van Essen,Jurjen M. Ruben,Aiko P. J. de Vries,Cees van Kooten,Stefan P. Berger,J. van den Born,Piet Gros,Lambertus P. van den Heuvel,Nicole C. A. J. van de Kar,Marc A. Seelen,Annick de Vries	8
13	The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing 2017 ·Multiple Sclerosis Journal ·Zoé L. E. van Kempen,Cyra E Leurs,Birgit I. Lissenberg‐Witte,Annick de Vries,Mike P. Wattjes,Theo Rispens,Joep Killestein	28
14	From natalizumab to fingolimod in eight weeks — Immunological, clinical, and radiological data in quest of the optimal switch 2017 ·Clinical Immunology ·Andrea Harrer,Georg Pilz,Katrin Oppermann,(unknown),(unknown),Elisabeth Haschke‐Becher,Theo Rispens,Annick de Vries,Mark R. McCoy,(unknown),Wolfgang Hitzl,Eugen Trinka,Jörg Kraus,Johann Sellner,Peter Wipfler	4
15	Altered brain activation to colorectal distention in visceral hypersensitive maternal‐separated rats 2012 ·Neurogastroenterology & Motility ·Mira M. Wouters,Sander Van Wanrooy,Cindy Casteels,Andrea Némethova,Annick de Vries,Lukas Van Oudenhove,René M. van den Wijngaard,Koen Van Laere,Guy E. Boeckxstaens	35
16	Diet and asthma — Can you change what you or your children are by changing what you eat? 2009 ·Pharmacology & Therapeutics ·Annick de Vries,Sarah Howie	9
17	Antibodies directed against nerve growth factor inhibit the acute bronchoconstriction due to allergen challenge in guinea‐pigs 2002 ·Clinical & Experimental Allergy ·Annick de Vries,Ferdi Engels,Paul A. J. Henricks,Thea Leusink-Muis,Axel Fischer,Frans P. Nijkamp	31
18	Virus- and Bradykinin-Induced Airway Hyperresponsiveness in Guinea Pigs 2000 ·American Journal of Respiratory and Critical Care Medicine ·Gert Folkerts,(unknown),Annick de Vries,(unknown),(unknown),Ferdi Engels,J.C. de Jong,Fons Verheyen,D. van Heuven-Nolsen,FRANS P. NIJKAMP	17
19	Excitatory non-adrenergic–non-cholinergic neuropeptides: key players in asthma 2000 ·European Journal of Pharmacology ·Aletta D. Kraneveld,(unknown),Annick de Vries,Frans P. Nijkamp	22
20	Nerve Growth Factor Induces a Neurokinin-1 Receptor– Mediated Airway Hyperresponsiveness in Guinea Pigs 1999 ·American Journal of Respiratory and Critical Care Medicine ·Annick de Vries,Mark C. Dessing,Ferdi Engels,Paul A. J. Henricks,FRANS P. NIJKAMP	116

About Annick de Vries

Annick de Vries is a scholar working on Immunology, Rheumatology and Gastroenterology, having authored 90 papers that have together received 1.9k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (17 papers), Biosimilars and Bioanalytical Methods (17 papers) and Microscopic Colitis (15 papers). The work is most often cited by research in Developmental Neuroscience (134 citations), Behavioral Neuroscience (113 citations) and Biological Psychiatry (64 citations). Annick de Vries has collaborated with scholars based in Netherlands, Belgium and United Kingdom. Frequent co-authors include Theo Rispens, Ferdi Engels, Paul A. J. Henricks, Jonathan R. Seckl, Mark C. Dessing, Frans P. Nijkamp, FRANS P. NIJKAMP, Geert D’Haens, Karien Bloem and Ron A. A. Mathôt. Their work appears in journals such as Journal of Clinical Investigation, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact